2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. nAChR
  4. 1026134-63-3

1026134-63-3

Nelonicline Chemical Structure

1026134-63-3

Chemical Structure

  • Nelonicline
  • Synonym(s): ABT-126
  • CAS No: 1026134-63-3
    Formula: C17H19N3OS
    Molecular Weight: 313.42
  • IUPAC Name: 2-(((1r,3R,4s,5S,7s)-1-azaadamantan-4-yl)oxy)-5-phenyl-1,3,4-thiadiazole
  • InChIKey: QZDCYUCETTWCMO-WTGKZIDZSA-N
  • SMILES: [C@@H]1([C@H]2C[C@H](C3)C[C@@H]1C[N@]3C2)OC4=NN=C(C5=CC=CC=C5)S4

Biological Activity: Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease[1][2][3].

Cat. No. Product Name Purity Description
HY-16748 Nelonicline 99.82% Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease.

References

[1]. Zhang D, et al. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015;30(14):1901-1911. [Content Brief]
[2]. Haig G, et al. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study. Neuropsychopharmacology. 2016;41(12):2893-2902. [Content Brief]
[3]. Gault LM, et al. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res Ther. 2016;8(1):44. Published 2016 Oct 18. [Content Brief]

Keywords:

Nelonicline